Trial Profile

A Phase 1 safety study of GRNOPC1 in patients with neurologically complete, subacute, spinal cord injury

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPC 1 (Primary)
Indications Spinal cord injuries
Focus Adverse reactions; First in man
Sponsors Asterias Biotherapeutics; Lineage Cell Therapeutics

Most Recent Events

13 Feb 2024 According to Lineage Cell Therapeutics media release, data from the study were presented at Journal of Neurosurgery: Spine.
31 Jul 2018 Updated results from the 25 subjects (SCiStar study) and 5 subjects from this Phase 1 safety study are presented in an Asterias Biotherapeutics media release.
21 Mar 2017 Results published in an Asterias Biotherapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com